

Anti-RSV [RSHZ19 (Felvizumab)] Standard Size Ab00729-15.0

This antibody does not have a J-chain and therefore presents as a hexamer, rather than a pentamer.

This reformatted antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgM, Kappa **Clone Number:** RSHZ19 (Felvizumab)

Alternative Name(s) of Target: SB 209763; respiratory syncytial virus

UniProt Accession Number of Target Protein:

Published Application(s): functional, ELISA

Published Species Reactivity: RSV

Immunogen: This antibody was prepared by the humanization of an F protein-specific murine MAb, RSV19. More specifically, molecular techniques were used to insert the complementarity determining regions from murine RSV19 into a human IgG1 heavy and k light chain-variable domain framework.

Specificity: This antibody is specific for the an epitope located between amino acids 417-432 of conserved fusion (F) protein of RSV.

Application Notes: Though shown to be safe and well-tolerated (Everitt, 1996) and protective against RSV infection in BALB/c mice and cotton rats (Wyde, 1995), this antibody did not demonstrate efficacy in a Phase 3 study (Reichert, 2008). In in vitro studies, palivizumab, another humanized Mab specific for the F protein of RSV, was 4 to 5-fold more potent than felvizumab in neutralising RSV (Scott, 1999).

Antibody First Published in: Tempest et al. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnology (N Y). 1991 Mar;9(3):266-71 PMID:1367535 **Note on publication:** Describes the original production of the humanized anti-RSV antibody from murine RSV19.

Product Form

Size: 50 μg Purified antibody.

Purification: Affinity Purified using a recombinant lectin column

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -

